WHO Launches Landmark Guideline to Bridge Global Gaps in Access to Controlled Medicines In a bold step toward improving global health equity, the World Health Organization (WHO) unveiled a new…
Eisai’s Lemborexant (DAYVIGO®) Receives Regulatory Approval in China for the Treatment of Insomnia Eisai Co., Ltd., a leading global pharmaceutical company headquartered in Tokyo and led by CEO Haruo Naito,…
Partnering for Progress: How Astellas and the Pompe Disease Community Are Shaping the Future Together Pompe disease is a rare, inherited, and progressively debilitating disorder that profoundly affects the lives…
Practice-Changing Data, Innovative Modalities, and Global Impact Headline ASCO 2025 The oncology community is converging in Chicago this week for the highly anticipated 2025 Annual Meeting of the American Society…
U.S. Vaccine Innovation at Risk: How Four Biotechs Are Being Squeezed by Shifting Policies, Funding Cuts, and Regulatory Changes As the World Health Organization (WHO) sets a new course for…
World Health Assembly Approves Extension of Global Digital Health Strategy to 2027 and Greenlights Next Phase for 2028–2033 In a landmark decision underscoring the accelerating global commitment to digital health,…
Cullinan Therapeutics and Taiho Highlight Promising Phase 2b Results of Zipalertinib in Advanced EGFR ex20ins NSCLC at ASCO 2025 Cullinan Therapeutics,in collaboration with Taiho Pharmaceutical Co., Ltd., and its U.S.…
Astellas and Pfizer Showcase Five-Year Survival Benefits of XTANDI in Metastatic Hormone-Sensitive Prostate Cancer at ASCO 2025 In a pivotal milestone for prostate cancer treatment, Astellas Pharma Inc. and Pfizer…
Bringing Research to the People: How Walgreens Clinical Trials is Revolutionizing Patient Engagement Over the past three years, Walgreens has made remarkable strides in democratizing access to clinical trials. Through…
Federal Judge Blocks Trump Administration’s Sweeping HHS Layoff and Reorganization Plan, Citing Lack of Legal Authority A federal judge in California has issued a significant legal blow to the Trump…
Bayer’s Eylea™ 8 mg Recommended for EU Approval with Extended 6-Month Treatment Interval for Major Retinal Diseases Bayer has today announced a significant milestone in the treatment of retinal diseases,…
GSK’s Blenrep Combinations Receive Positive CHMP Opinion for Relapsed or Refractory Multiple Myeloma, Signaling Expanded Access Across Europe In a significant step forward for the treatment of multiple myeloma, GSK…